search

Active clinical trials for "Hyperlipidemias"

Results 691-695 of 695

A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial)

Hyperlipidemias

In this study, within the secondary prevention group patients ( diabetes mellitus, coronary artery disease, peripheral artery disease, who have had events atherosclerotic cerebrovascular ) , statin use requirement , patients compliance and reaching target LDL-cholesterol levels (according to European guidelines ) will be evaluated.

Unknown status6 enrollment criteria

Lipoprotein and Apolipoproteins With Metabolic Liver Diseases

Disorders of Lipoprotein Metabolism and Other Lipidaemias

Theranostic translation applications against viral, metabolic liver diseases and hepatic oncogenesis: lipoprotein and apolipoproteins at a crossroad

Unknown status5 enrollment criteria

Genetic Influence on Statin Pharmacodynamics

HyperlipidemiaHypercholesterolemia1 more

The study intends to investigate whether genetics influence how individuals respond to statins (clinical outcomes and changes in carotid intimal media thickness)

Withdrawn2 enrollment criteria

Comparison of LDL Particle Count With Other Available Lipid Tests

Hyperlipidemia

Despite the wide availability of advanced lipoprotein tests, no reference standard exists for Low Density Lipoprotein Cholesterol (LDL-C) due to inherent problems with each of the assays. Newer methods for estimating LDL particle numbers, including nuclear magnetic resonance (NMR) spectroscopy and vertical auto profile (VAP) are currently under investigation. NMR has been proposed as having the best correlation with adverse cardiovascular outcomes. Unfortunately, the accuracy of LDL-C or LDL particle number measurements is currently not monitored by national standardization programs. Direct comparisons between the various testing methods have been limited restricting our ability to accurately interpret and compare values across vendors and lipid parameters. Our hypothesis is that: LDL particle count numbers, as determined by NMR (Liposcience), provides the best estimates of cardiovascular risk. Discrepancies exist between the LDL particle count by NMR and other values as presented by calculated LDLC and directly measured LDL (VAP and ion mobility). The investigators will enroll 100 patients recruited from the Lipid Clinic at the Scripps Center for Integrative Medicine. Each patient will have one blood draw from which four tests will be analyzed. Risks are associated with drawing blood, which will be minimized by using Scripps Clinic Lab technicians. The potential loss of personal health information will be reduced by limiting access to study and lab staff and keeping information password-protected on Scripps servers.

Unknown status3 enrollment criteria

Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)

HealthyMetabolic Syndrome X3 more

The metabolic syndrome is a highly prevalent disorder, which causes atherosclerotic cardiovascular disease and is closely associated with insulin resistance. The alteration of the secretion of adipocytokines from accumulated visceral adipose tissue in the obese induces insulin resistance. The purpose of this study is to identify gene polymorphisms that confer susceptibility to the metabolic syndrome and to make up a new health guidance program based on genetic risk assessment. About 25% of male employees over 45 years old in a certain company are diagnosed with the metabolic syndrome in medical examination. We, the researchers at Nagoya University, will analyze gene polymorphism and various biomarkers of over 3500 company employees.

Unknown status1 enrollment criteria
1...6970

Need Help? Contact our team!


We'll reach out to this number within 24 hrs